InflaRx advances izicopan development and launches $150 million stock offering

3 articles · Updated · MarketWatch · May 6

The German biopharmaceutical company said it is planning Phase 2 trials in ANCA-associated vasculitis and will sell 75 million shares at $2 each, with the offering expected to close Thursday.
Its shares rose 29% to $2.54 after the announcement, and the company said proceeds would fund pipeline activities and general corporate purposes.
InflaRx is also pursuing proof-of-concept studies in atypical hemolytic uremic syndrome, IgA nephropathy and C3 glomerulopathy, with clinical data expected next year and funding projected through 2029.

As its rival faces a potential ban, can InflaRx’s new drug become the safer standard for this severe kidney disease?

Is this the next breakthrough in the 'renal renaissance,' or just another hopeful in an increasingly crowded field of treatments?